Rafael Amado - 30 Dec 2025 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
30 Dec 2025
Net transactions value
-$188,039
Form type
4
Filing time
02 Jan 2026, 16:15:40 UTC
Previous filing
12 Aug 2025
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Amado Rafael President, Head of Global Oncology Research and Development C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE /s/ Bruce Blefeld, Attorney-in-Fact 02 Jan 2026 0001662119

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +21,000 +50% 63,178 30 Dec 2025 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale $188,039 -10,787 -17% $17.43 52,391 31 Dec 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -21,000 -33% $0.000000 42,000 30 Dec 2025 American Depositary Shares 21,000 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3 Each RSU represents a contingent right to receive one ADS.
F4 These ADSs were sold automatically to cover taxes upon vesting of RSUs.
F5 These RSUs vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development